Is everolimus a targeted drug or a chemotherapy drug?

Everolimus is a targeted drug, not a chemotherapy drug. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor and a semi-synthetic derivative of sirolimus (rapamycin). It interferes with the growth and proliferation of tumor cells by inhibiting the mTOR signaling pathway. This mechanism of action makes everolimus a targeted therapy drug that can act on tumor cells more precisely and reduce damage to normal cells.

Everolimus is mainly used clinically to treat patients who have failed first-line targeted drug therapy, especially renal cell carcinoma after first-line targeted drug therapy has failed. In addition, it can be used to treat advanced neuroendocrine tumors, tuberous sclerosis-related renal angiomyolipoma, and prevent rejection after organ transplantation. These applications all reflect the accuracy and pertinence of everolimus as a targeted drug.

Chemotherapy drugs usually kill or inhibit the growth of tumor cells by interfering with the cells' DNA synthesis or function. These drugs often have a killing effect on both normal cells and tumor cells, so they have serious side effects. As a targeted drug, everolimus can act on tumor cells more accurately and reduce damage to normal cells, thus reducing side effects.

Although the side effects of everolimus are relatively minor, some adverse reactions may still occur, such as non-infectious pneumonia, infection, oral ulcers, renal failure, etc. Therefore, when using everolimus, it is recommended to proceed under the guidance of a professional physician, and adjust the dosage and regimen according to the patient's specific conditions.

Since the safe range of everolimus' blood concentration is narrow, the pharmacokinetics of everolimus vary greatly between individuals and are easily affected by other drugs or food ingredients. Therefore, when used in combination with other drugs, therapeutic drug monitoring is required to adjust the dosage and ensure the effectiveness and safety of the drug.